1-2 of 2
Keywords: BRAF
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo

Angela Clerk, Daniel N. Meijles, Michelle A. Hardyman, Stephen J. Fuller, Sonia P. Chothani, Joshua J. Cull, Susanna T.E. Cooper, Hajed O. Alharbi, Konstantinos Vanezis, Leanne E. Felkin, Thomais Markou, Samuel J. Leonard, Spencer W. Shaw, Owen J.L. Rackham, Stuart A. Cook, Peter E. Glennon, Mary N. Sheppard, John C. Sembrat, Mauricio Rojas, Charles F. McTiernan, Paul J. Barton, Peter H. Sugden
Journal: Biochemical Journal
Biochem J (2022) 479 (3): 401–424.
https://doi.org/10.1042/BCJ20210615
Published: 11 February 2022
... to determine if BRAF is relevant for human heart failure, whether BRAF promotes cardiomyocyte hypertrophy, and if Type 1 RAF inhibitors developed for cancer (that paradoxically activate ERK1/2 at low concentrations: the ‘RAF paradox') may have the same effect. BRAF was up-regulated in heart samples from...
View article titled, Cardiomyocyte <span class="search-highlight">BRAF</span> and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo
Open the PDF for Cardiomyocyte <span class="search-highlight">BRAF</span> and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo in another window
Includes: Supplementary data
Articles

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance

Matthew J. Sale, Simon J. Cook
Journal: Biochemical Journal
Biochem J (2013) 450 (2): 285–294.
https://doi.org/10.1042/BJ20121212
Published: 15 February 2013
... survival of colorectal cancer and melanoma cell lines with BRAF V600E or RAS mutations. This cell death absolutely required BAX (BCL2-associated X protein) and was inhibited by RNAi (RNA interference)-mediated knockdown of BIM (BCL2-interacting mediator of cell death) in the BRAF V600E -positive COLO205...
View article titled, The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
Open the PDF for The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance in another window
Includes: Supplementary data